Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst S.r.l. Irccs
Clinical trials sponsored by Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst S.r.l. Irccs, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New combo therapy aims to stall prostate cancer spread Results expected Sep 2027 (estimated)
-
Can time with horses help cancer patients feel better?
Symptom relief CompletedResearchers are testing whether a structured program of interactions with horses improves quality of life for young people and women who have finished chemotherapy or radiotherapy for cancer or blood disorders. Participants are randomly assigned to receive standard follow-up care…
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Symptom relief
Last updated Sep 21, 2026 20:00 UTC
-
E-Learning could sharpen Doctors' eye for skin cancer
Knowledge-focused CompletedThis trial tests whether an online training course, called MelaMEd, can improve primary care doctors' ability to detect and manage melanoma, the most serious form of skin cancer. Participants—general practitioners, trainees, and pediatricians—answer questions and review skin lesi…
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
New study aims to improve timing of palliative care for advanced illnesses
Knowledge-focused CompletedThis completed study observed 178 patients with advanced cancer, chronic kidney failure, or chronic lung diseases to assess their palliative care needs and survival factors. Researchers used two scoring tools to evaluate when and how to best introduce palliative care alongside re…
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Italian study reveals Real-World impact of targeted leukemia drug
Knowledge-focused CompletedThis study looked back at the medical records of 84 people with acute lymphoblastic leukemia (ALL) who received a drug called anti-CD22 outside of clinical trials. The goal was to see how safe and effective the treatment was in everyday hospital use. Researchers collected informa…
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
App vs. paper: which diary boosts cancer pill adherence?
Knowledge-focused CompletedThis study tested whether an electronic diary app helps cancer patients take their oral medications more consistently than a traditional paper diary. A total of 124 adults with solid tumors or blood cancers were randomly assigned to use either the app or a paper diary to track th…
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC